DJIA 16,102.38 -272.38 -1.66%
NASDAQ 4,683.92 -49.58 -1.05%
S&P 500 1,921.22 -29.91 -1.53%
market minute promo

AbbVie Inc. (NYSE: ABBV)

59.77 -1.81 (-2.94%)

Quote as of


company name or ticker

Recent Quotes

ABBV $59.77 -2.94%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $60.65
Previous Close $61.58
Daily Range $58.96 - $60.80
52-Week Range $52.06 - $71.60
Market Cap $98.9B
P/E Ratio 48.11
Dividend (Yield) $2.04 (3.3%)
Ex-Dividend Date
Dividend Pay Date
07/13/15
08/14/15
Volume 9,272,658
Average Daily Volume 10,477,871
Current FY EPS $4.26

Sector

Industry

AbbVie Inc. (ABBV) Description

AbbVie Inc. Website: http://www.abbvie.com/

News & Commentary

A $25 Billion Hedge Fund Just Made AbbVie One of Its Biggest Bets

AbbVie Inc. could end up sidestepping lost sales tied to an expiring patent on Humira in 2017.

Tactical Dividend Growth: Buying Biotech, Assessing Market Volatility

Noteworthy ETF Outflows: IYH, ABBV, MDT, BIIB

Can Top 10 Healthcare Dogs Average 25% Upsides And 27% Net Gains As Of September 2016?

Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up

3 Merger Arbitrage Opportunities

Bristol-Myers/AbbVie Cancer Drug Gets Priority Review

U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for

U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies

After Hours Most Active for Aug 31, 2015 : TV, MSFT, QQQ, ABBV, GE, INTC, EXEL, FTR, T, PFE, FB, F

After Hours Most Active for Aug 31, 2015 : TV, MSFT, QQQ, ABBV, GE, INTC, EXEL, FTR, T, PFE, FB, F

Amgen Poised To Dominate A $32 Billion Biosimilar Market

CELG, PFE, REGN, RCPT Jim Cramer's Views

See More ABBV News...